MEDICENNA THERAPEUTICS CORP (MDNA) Stock Price, Quote, News and Overview
NASDAQ:MDNA - Nasdaq - CA58490H1073 - Common Stock - Currency: USD
MDNA Quote, Performance and Key Statistics
0.157
-0.02 (-13.16%)
The current stock price of MDNA is 0.157 USD. In the past month the price decreased by -43.73%. In the past year, price decreased by -75.7%.
MDNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.73 | 340.25B | ||
| AMGN | AMGEN INC | 14.28 | 152.20B | ||
| GILD | GILEAD SCIENCES INC | 13.74 | 132.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1712.03 | 127.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.38 | 66.78B | ||
| ARGX | ARGENX SE - ADR | 326.83 | 37.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
| NTRA | NATERA INC | N/A | 20.68B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.78B | ||
| BIIB | BIOGEN INC | 7.23 | 17.44B |
Related stock screener links
About MDNA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
MEDICENNA THERAPEUTICS CORP
2 Bloor St W 7th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Fahar Merchant
Employees: 18
Company Website: https://www.medicenna.com
Phone: 14166485555.0
MEDICENNA THERAPEUTICS CORP / MDNA FAQ
What is the stock price of MEDICENNA THERAPEUTICS CORP today?
The current stock price of MDNA is 0.157 USD. The price decreased by -13.16% in the last trading session.
What is the ticker symbol for MEDICENNA THERAPEUTICS CORP stock?
The exchange symbol of MEDICENNA THERAPEUTICS CORP is MDNA and it is listed on the Nasdaq exchange.
On which exchange is MDNA stock listed?
MDNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MEDICENNA THERAPEUTICS CORP stock?
11 analysts have analysed MDNA and the average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157. Check the MEDICENNA THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA) has a market capitalization of 10.93M USD. This makes MDNA a Nano Cap stock.
How many employees does MEDICENNA THERAPEUTICS CORP have?
MEDICENNA THERAPEUTICS CORP (MDNA) currently has 18 employees.
Should I buy MEDICENNA THERAPEUTICS CORP (MDNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDNA, evaluating the profitability, health, valuation and growth aspects
- MEDICENNA THERAPEUTICS CORP (MDNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDICENNA THERAPEUTICS CORP (MDNA) Sales and EPS estimates to see what analysts future expectations are.
- MEDICENNA THERAPEUTICS CORP (MDNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDICENNA THERAPEUTICS CORP (MDNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDICENNA THERAPEUTICS CORP (MDNA) Stock Chart to make your own analysis
- MEDICENNA THERAPEUTICS CORP (MDNA) Latest news and press-releases to stay up to date.
Does MEDICENNA THERAPEUTICS CORP (MDNA) stock pay dividends?
MDNA does not pay a dividend.
When does MEDICENNA THERAPEUTICS CORP (MDNA) report earnings?
MEDICENNA THERAPEUTICS CORP (MDNA) will report earnings on 2023-11-09, before the market open.
What is the Price/Earnings (PE) ratio of MEDICENNA THERAPEUTICS CORP (MDNA)?
MEDICENNA THERAPEUTICS CORP (MDNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
MDNA Technical Analysis
MDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDNA. No worries on liquidiy or solvency for MDNA as it has an excellent financial health rating, but there are worries on the profitability.
MDNA Financial Highlights
Over the last trailing twelve months MDNA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 56.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| Debt/Equity | 0 |
MDNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to MDNA. The Buy consensus is the average rating of analysts ratings from 11 analysts.